medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-10-49-55medsovet-2532Research ArticleХимиотерапия злокачественных опухолейMalignant tumor chemotherapyВозможности терапии больных с предлеченным трижды негативным раком молочной железы комбинацией цисплатина и наб-паклитаксела. Описание клинического случаяThe prospects for cisplatin and nab-paclitaxel combination therapy in patients with pre-treated triple-negative breast cancer. Description of the clinical case.ЖуковаЛ. Г.ZhukovaL. G.БардовскаяК. С.BardovskayaK. S.ЛубенниковаЕ. В.LubennikovaE. V.СусловаИ. Р.SuslovaI. R.

Oncology Centre No. 4 of the Moscow Department of Health

ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииРоссияBlokhin Russian Medical Research Centre of Oncology of the Ministry of Health of RussiaRussian FederationГБУЗ «Московский клинический научный центр им. А.С. Логинова» Департамента здравоохранения г. МосквыРоссияLoginov Moscow Clinical Research Center of the Moscow Department of HealthRussian FederationГБУЗ «Онкологический диспансер №4 Департамента здравоохранения г. Москвы»РоссияOncology Centre No. 4 of the Moscow Department of HealthRussian Federation2018180720180104955Copyright © Жукова Л.Г., Бардовская К.С., Лубенникова Е.В., Суслова И.Р., 20182018Жукова Л.Г., Бардовская К.С., Лубенникова Е.В., Суслова И.Р.Zhukova L.G., Bardovskaya K.S., Lubennikova E.V., Suslova I.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2532

Молекулярно-биологические особенности трижды негативного рака молочной железы (ТН РМЖ) определяют ограниченные возможности системной терапии и, как следствие, более агрессивное течение болезни. Среди химиопрепаратов, используемых в терапии РМЖ, таксаны являются одними из наиболее эффективных. Особая форма паклитаксела – набпаклитаксел – позволяет получить объективный и, что особенно важно у предлеченных больных, субъективный эффект, при этом препарат имеет благоприятный профиль безопасности и хорошо управляемую токсичность.

В статье представлен обзор литературы о перспективах применения наб-паклитаксела при РМЖ, особенно при его трижды негативном варианте, а также приведено описание клинического случая терапии комбинацией цисплатина и набпаклитаксела у молодой больной с BRCA-1-ассоциированным ТН РМЖ.

Molecular and biological features of triple negative breast cancer (TN BC) determine the limited possibilities of systemic therapy and, as a consequence, the more aggressive course of the disease. Taxanes are one of the most effective chemotherapies used in breast cancer therapy. The special form of paclitaxel nab-paclitaxel makes it possible to obtain an objective and a subjective effect, which is especially important in the pre-treated patients. In addition, the drug has a favourable safety profile and a well-controlled toxicity.

The article contains a review of the literature on the prospects for the use of nab-paclitaxel in breast cancer, especially in its triple negative version, and a description of the clinical case of therapy with a combination of cisplatin and nab-paclitaxel in a young patient with BRCA-1-associated TN breast cancer.

трижды негативный рак молочной железытаксанынаб-паклитакселtriple negative breast cancertaxanesnab-paclitaxelReferencesКаприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2018. 250 с.Kaprin AD, Starinsky VV, Petrova GV. Malignant neoplasms in Russia in 2016 (morbidity and mortality). Moscow: Herzen Medical Research Cancer Institute, a branch of National Medical Research Radiology Institute of the Ministry of Health of Russia. 2018. 250 p.Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature, 2000, 406: 747–52.Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature, 2000, 406: 747–52.Metzger-Filho O, Tutt A, de Azambuja E et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol, 2012, 30: 1879–87.Metzger-Filho O, Tutt A, de Azambuja E et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol, 2012, 30: 1879–87.Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol, 2012, 23(Suppl. 6): vi7–vi12.Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol, 2012, 23(Suppl. 6): vi7–vi12.Alba E, Chacon JI, Lluch A, et al. A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat, 2012, 136(2): 487–493.Alba E, Chacon JI, Lluch A, et al. A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat, 2012, 136(2): 487–493.Conlin AK, Seidman AD. Taxanes in breast cancer: an update. Curr Oncol Rep, 2007, 9: 22-30.Conlin AK, Seidman AD. Taxanes in breast cancer: an update. Curr Oncol Rep, 2007, 9: 22-30.John TA, Vogel SM, Tiruppathi C, et al. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol, 2003, 284(1): L187-96.John TA, Vogel SM, Tiruppathi C, et al. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol, 2003, 284(1): L187-96.Desai N. Nab technology: a drug delivery platform utilising endothelial gp60 receptor-based transport and tumour-derived SPARC for targeting. Drug Delivery Report 16th edition. 2007/2008: 37-41.Desai N. Nab technology: a drug delivery platform utilising endothelial gp60 receptor-based transport and tumour-derived SPARC for targeting. Drug Delivery Report 16th edition. 2007/2008: 37-41.Schettini F, Giuliano M, et al. Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives. Cancer Treat Rev, 2016 Nov, 50: 129-141.Schettini F, Giuliano M, et al. Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives. Cancer Treat Rev, 2016 Nov, 50: 129-141.Sen S, Kato S, Agarwal R, et al. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer, 2018, Apr 26.Sen S, Kato S, Agarwal R, et al. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer, 2018, Apr 26.FDA. ABRAXANE! for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). 2007. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2008/021660s013lbl.pdf.FDA. ABRAXANE! for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). 2007. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2008/021660s013lbl.pdf.Инструкция к медицинскому применению препарата Абраксан: ЛСР-009047/10-230817./ Patient Information Leaflet for Abraxan: LSR009047/10-230817.Инструкция к медицинскому применению препарата Абраксан: ЛСР-009047/10-230817./ Patient Information Leaflet for Abraxan: LSR009047/10-230817.Untch M, Jackisch C, Schneeweiss A, et al. Nabpaclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto–GBG 69): a randomised, phase 3 trial. Lancet Oncol, 2016, 17(Issue 3): 345-356.Untch M, Jackisch C, Schneeweiss A, et al. Nabpaclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto–GBG 69): a randomised, phase 3 trial. Lancet Oncol, 2016, 17(Issue 3): 345-356.Schneeweiss A. SABCS 2017.Schneeweiss A. SABCS 2017.Gianni L, Mansutti M, Anton A, et al. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. JAMA Oncol, 2018 Mar 1, 4(3): 302-308.Gianni L, Mansutti M, Anton A, et al. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. JAMA Oncol, 2018 Mar 1, 4(3): 302-308.Ueno NT, Mamounas EP. Neoadjuvant nabpaclitaxel in the treatment of breast cancer. Breast Cancer Research and Treatment, 2016, 156: 427-440.Ueno NT, Mamounas EP. Neoadjuvant nabpaclitaxel in the treatment of breast cancer. Breast Cancer Research and Treatment, 2016, 156: 427-440.Silver DP, Richardson AL, Eklund AC, et al. Efficacy of Neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol, 2011, 28(7): 1145–1153.Silver DP, Richardson AL, Eklund AC, et al. Efficacy of Neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol, 2011, 28(7): 1145–1153.Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol, 2008, 26(24): 3950–3957.Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol, 2008, 26(24): 3950–3957.Gluz O, Nitz U, et al. Comparison of Neoadjuvant Nab-Paclitaxel1Carboplatin vs Nab-Paclitaxel1Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results. JNCI J Natl Cancer Inst, 2018, 110(6): djx258.Gluz O, Nitz U, et al. Comparison of Neoadjuvant Nab-Paclitaxel1Carboplatin vs Nab-Paclitaxel1Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results. JNCI J Natl Cancer Inst, 2018, 110(6): djx258.Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol, 2005, 23(31): 7794-803.Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol, 2005, 23(31): 7794-803.Ciruelos E, Christian Jackisch. paclitaxel (Abraxane) in women with aggressive metastatic breast cancer Expert Rev. Anticancer Ther, 2014, 14(5): 511–521.Ciruelos E, Christian Jackisch. paclitaxel (Abraxane) in women with aggressive metastatic breast cancer Expert Rev. Anticancer Ther, 2014, 14(5): 511–521.Bernardo A, Palumbo R, Pedersini R, et al. NabPaclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials. Clinical Breast Cancer, 2017 Oct, 17(6): 433-440.Bernardo A, Palumbo R, Pedersini R, et al. NabPaclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials. Clinical Breast Cancer, 2017 Oct, 17(6): 433-440.Sun S, Tang L, Zhang J, et al. Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer. International Journal of Nanomedicine, 2014, 9: 1443-1452.Sun S, Tang L, Zhang J, et al. Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer. International Journal of Nanomedicine, 2014, 9: 1443-1452.Yardley DA, Coleman R, Conte P, et al. nabPaclitaxel Plus Carboplatin or Gemcitabine vs Gemcitabine Plus Carboplatin as First-Line Treatment for Patients With Triple-Negative Metastatic Breast Cancer: Results From the tnAcity Trial. Downloaded from https://academic.oup.com/annonc/advance-article-abstract/ doi/10.1093/annonc/mdy201/5033593.Yardley DA, Coleman R, Conte P, et al. nabPaclitaxel Plus Carboplatin or Gemcitabine vs Gemcitabine Plus Carboplatin as First-Line Treatment for Patients With Triple-Negative Metastatic Breast Cancer: Results From the tnAcity Trial. Downloaded from https://academic.oup.com/annonc/advance-article-abstract/ doi/10.1093/annonc/mdy201/5033593.Barton VN, Gordon MA, Richer JK, Elias A. Antiandrogen therapy in triple-negative breast cancer. Therapeutic Advances in Medical Oncology, 2016, 8(4): 305-308.Barton VN, Gordon MA, Richer JK, Elias A. Antiandrogen therapy in triple-negative breast cancer. Therapeutic Advances in Medical Oncology, 2016, 8(4): 305-308.Robson M, Seock-Ah Im, Senkus E. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med, 2017, 377: 523-533.Robson M, Seock-Ah Im, Senkus E. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med, 2017, 377: 523-533.

The authors declare that there are no conflicts of interest present.